Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

Similar articles for PubMed (Select 20723033)

1.

A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.

Fuji T, Fujita S, Tachibana S, Kawai Y.

J Thromb Haemost. 2010 Nov;8(11):2458-68. doi: 10.1111/j.1538-7836.2010.04021.x.

PMID:
20723033
2.

Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.

Zahir H, Brown KS, Vandell AG, Desai M, Maa JF, Dishy V, Lomeli B, Feussner A, Feng W, He L, Grosso MA, Lanz HJ, Antman EM.

Circulation. 2015 Jan 6;131(1):82-90. doi: 10.1161/CIRCULATIONAHA.114.013445. Epub 2014 Nov 17. Erratum in: Circulation. 2015 Jan 6;131(1):e10.

PMID:
25403645
3.

Edoxaban: an investigational factor xa inhibitor.

Hughes GJ, Hilas O.

P T. 2014 Oct;39(10):686-715.

4.

Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.

Fuji T, Wang CJ, Fujita S, Kawai Y, Kimura T, Tachibana S.

J Arthroplasty. 2014 Dec;29(12):2439-46. doi: 10.1016/j.arth.2014.05.029. Epub 2014 Jun 9.

5.

Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment.

Song S, Kang D, Halim AB, Miller R.

J Clin Pharmacol. 2014 Aug;54(8):910-6. doi: 10.1002/jcph.306. Epub 2014 May 2.

PMID:
24706516
6.

The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism.

Escolar G, Diaz-Ricart M, Arellano-Rodrigo E, Galán AM.

Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):445-58. doi: 10.1517/17425255.2014.882897. Epub 2014 Jan 28. Review.

PMID:
24471416
7.
8.

Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery.

Kuroda Y, Hirayama C, Hotoda H, Nishikawa Y, Nishiwaki A.

Vasc Health Risk Manag. 2013;9:593-8. doi: 10.2147/VHRM.S51244. Epub 2013 Oct 7.

9.

Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty.

Sasaki H, Ishida K, Shibanuma N, Tei K, Tateishi H, Toda A, Yamashiro Y, Matsumoto T, Kuroda R, Kurosaka M.

Int Orthop. 2014 Mar;38(3):525-9. doi: 10.1007/s00264-013-2132-x. Epub 2013 Oct 8.

10.

An adaptive-design dose-ranging study of PD 0348292, an oral factor Xa inhibitor, for thromboprophylaxis after total knee replacement surgery.

Cohen AT, Boyd RA, Mandema JW, Dicarlo L, Pak R; A5571010 Investigators.

J Thromb Haemost. 2013 Aug;11(8):1503-10. doi: 10.1111/jth.12328.

PMID:
23782955
11.

The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.

Mendell J, Lee F, Chen S, Worland V, Shi M, Samama MM.

J Cardiovasc Pharmacol. 2013 Aug;62(2):212-21. doi: 10.1097/FJC.0b013e3182970991.

PMID:
23615159
12.

Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.

Rohatagi S, Mendell J, Kastrissios H, Green M, Shi M, Patel I, Salazar DE.

Thromb Haemost. 2012 Nov;108(5):887-95. doi: 10.1160/TH12-03-0184. Epub 2012 Sep 26.

PMID:
23014669
13.

Oral anticoagulation with edoxaban. Focus on current phase III clinical development.

Ahrens I, Bode C.

Hamostaseologie. 2012;32(3):212-5. doi: 10.5482/HAMO-12-05-0004. Epub 2012 Jul 12.

PMID:
22786687
14.

Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.

Zahir H, Matsushima N, Halim AB, He L, Zhang G, Lee F, Worland V, Mendell J.

Thromb Haemost. 2012 Jul;108(1):166-75. doi: 10.1160/TH11-09-0676. Epub 2012 May 25.

PMID:
22628060
15.

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.

Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, Patel I, Bocanegra TS, Antman EM, Giugliano RP, Kunitada S, Dornseif B, Shi M, Tachibana M, Zhou S, Rohatagi S.

Thromb Haemost. 2012 May;107(5):925-36. doi: 10.1160/TH11-08-0566. Epub 2012 Mar 8.

PMID:
22398655
16.

Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.

Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T.

Thromb Haemost. 2012 Feb;107(2):253-9. doi: 10.1160/TH11-09-0668. Epub 2011 Dec 21.

PMID:
22186946
17.

Edoxaban for the prevention of thromboembolic events after surgery.

Gras J.

Drugs Today (Barc). 2011 Oct;47(10):753-61. doi: 10.1358/dot.2011.47.10.1709241. Review.

PMID:
22076490
18.

Edoxaban: pharmacological principles, preclinical and early-phase clinical testing.

Partida RA, Giugliano RP.

Future Cardiol. 2011 Jul;7(4):459-70. doi: 10.2217/fca.11.28.

PMID:
21797743
19.

Edoxaban tosylate.

[No authors listed]

Am J Cardiovasc Drugs. 2011;11(2):129-35. doi: 10.2165/11533660-000000000-00000. Review.

PMID:
21446778
20.

Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial.

Verhamme P, Tangelder M, Verhaeghe R, Ageno W, Glazer S, Prins M, Jacquemin M, Büller H; TB-402 Study Group.

J Thromb Haemost. 2011 Apr;9(4):664-71. doi: 10.1111/j.1538-7836.2011.04221.x.

PMID:
21284801
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk